The AstraZeneca share $AZN (+2.97%) is currently in a positive state. The pharmaceutical company has published promising results on a new drug for the treatment of breast cancer, Camizestrant. These data come from a phase III trial and show a significant extension of the period without disease progression.
The trial is still ongoing and it is likely to be some time before approval. However, analysts are optimistic and forecast sales of USD 1.5 billion (EUR 1.4 billion) for Camizestrant by 2030.
AstraZeneca even expects peak annual sales of USD 5 billion for the drug, which would be a great success. Group CEO Pascal Soriot recently emphasized that the company's drug pipeline is well on track, which is reflected in sales growth of 18% in 2024 to over USD 54 billion.
AstraZeneca shares rose by 1.5% to £120.32 in London trading. It remains exciting to see how developments will continue! 📈